ライフサイエンスコーパス: bone mineral

1 llographically and structurally differs from bone mineral.

2 entration in bone increased by 0.39 mug Gd/g bone mineral +/- 0.14 per 1 mL of GBCA administered.

3 an in control subjects (mean, -1.06 mug Gd/g bone mineral +/- 0.71) (P = .01).

4 her in exposed subjects (mean, 1.19 mug Gd/g bone mineral +/- 0.73 [standard deviation]) than in cont

5 n frequent bursts of oral corticosteroids on bone mineral accretion in this regard.

6 on in infancy is required to support healthy bone mineral accretion.

7 ood interventions generally had no effect on bone mineral acquisition or body composition either with

8 en, is the aggressive and persistent loss of bone mineral and structural elements leading to loss of

9 Bone minerals are acquired during growth and are key det

10 erial was found to be similar to that of the bone mineral component of NIST SRM 1486 (bone meal), as

11 itudinal modelling of BMD and its components bone mineral content (BMC) and bone area (BA), from 9 to

12 total femur, femoral neck, and lumbar spine bone mineral content (BMC) and bone mineral density (BMD

13 Bone mineral content (BMC) and bone mineral density (BMD

14 at ages 6, 14, 17, and 20 y, and whole-body bone mineral content (BMC) and bone mineral density (BMD

15 ential nutrients that are needed to increase bone mineral content (BMC) and potentially decrease frac

16 n D during pregnancy have greater whole-body bone mineral content (BMC) at birth than those of mother

17 h bone mineral density (BMD), bone area, and bone mineral content (BMC) in a cohort of young adults.

18 rease in femoral neck and total body BMD and bone mineral content (BMC) in the WM group than in the W

19 We sought to compare whole-body bone mineral content (BMC) of newborns exposed vs not ex

20 f whole-body (WB) and skeletal site-specific bone mineral content (BMC) relative to linear growth in

21 de association study of areal BMD (aBMD) and bone mineral content (BMC) Z-scores measured by dual ene

22 pring total body bone mineral density (BMD), bone mineral content (BMC), and bone area (BA) were meas

23 crestal bone width (CBW), bone volume (BV), bone mineral content (BMC), and bone mineral density (BM

24 bgroup at 2 y of age : Bone mineral density, bone mineral content (BMC), area-adjusted BMC, and bone

25 rged the radio-opaque area and increased the bone mineral content and density in the radiological ana

26 assessed every 6 mo included the total-body bone mineral content and density, cortical and trabecula

27 rolone improves lean body mass accretion and bone mineral content and that the administration of the

28 ificantly increased bone mineral density and bone mineral content in femurs and lumbar vertebrae when

29 The adjusted mean bone mineral content was 5.3 g lower (95% confidence int

30 composition, including fat mass, lean mass, bone mineral content, and bone mineral density, was dete

31 d2 for several T cell measures and Prkca for bone mineral content.

32 over markers and a positive association with bone mineral content.

33 Similarly, changes in spine and femoral neck bone mineral contents (BMCs) were not significantly diff

34 l: the thin, plate-like morphology of mature bone mineral crystals, the presence of significant quant

35 one chips combined with deproteinized bovine bone mineral (DBBM) and a collagen barrier membrane has

36 most apical part) using deproteinized bovine bone mineral (DBBM) combined with either enamel matrix p

37 DXA (reference standard) to determine areal bone mineral densities (BMDs), and (c) quantitative CT w

38 95% CI -0.01, 0.01]; p = 0.80; n = 127,587); bone mineral density (0.01 g/cm(2) [95% CI -0.01, 0.03];

39 %, 95% CI 1.54 to 5.89; p=0.26), nor did hip bone mineral density (2.09%, 95% CI -1.45 to 5.63 vs 0.0

40 al women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the l

41 ary endpoint was the percent change in areal bone mineral density (aBMD) of the lumbar spine (LS), as

42 are variables that are not captured by areal bone mineral density (aBMD), and dietary protein intakes

43 Condylar bone mineral density (BMD) (computed tomography Hounsfie

44 l risedronate for prevention of reduction in bone mineral density (BMD) after 3 years of follow-up in

45 We investigated long-term changes in bone mineral density (BMD) among kidney transplant recip

46 ondition associated with progressive loss of bone mineral density (BMD) and compromised bone strength

47 ody mass, shortened body length, and reduced bone mineral density (BMD) and content (BMC) first evide

48 c skeletal disorder characterized by reduced bone mineral density (BMD) and disrupted bone architectu

49 te the relationship of PD with osteoporosis, bone mineral density (BMD) and fracture risk.

50 ociation studies (GWASs) identified multiple bone mineral density (BMD) and fracture-associated loci.

51 hoblastic leukemia (ALL) are at risk for low bone mineral density (BMD) and frail health, outcomes po

52 have increased fracture risk, despite normal bone mineral density (BMD) and high BMI-factors that are

53 tary patterns that explain most variation in bone mineral density (BMD) and hip bone geometry are ass

54 tis C virus (HCV) is associated with reduced bone mineral density (BMD) and increased fracture rates,

55 g CAC progression, including measurements of bone mineral density (BMD) and novel bone markers in adu

56 Whether PM is associated with loss of bone mineral density (BMD) and risk of bone fractures is

57 Children with cancer may develop low bone mineral density (BMD) any time before or after diag

58 Bone mineral content (BMC) and bone mineral density (BMD) are positively correlated wit

59 ndependently predict fracture risk and, with bone mineral density (BMD) assessed by X-ray (DXA), may

60 one density contributing to lower volumetric bone mineral density (BMD) at both distal radius and tib

61 hip, and non-vertebral fractures as well as bone mineral density (BMD) at the lumbar spine, total hi

62 ng the relationship between dairy intake and bone mineral density (BMD) because they are unable to co

63 ce imaging in 215 healthy army recruits, and bone mineral density (BMD) by Dual X-Ray Absorptiometry

64 Changes in bone turnover markers, bone mineral density (BMD) by dual-energy x-ray absorpti

65 Bone mineral density (BMD) changes and fracture rate.

66 We compared adjusted bone mineral density (BMD) changes between human immunod

67 ave a protective effect on lumbar spine (LS) bone mineral density (BMD) compared with lower protein i

68 Little is known about bone mineral density (BMD) during pregnancy.

69 endpoint was percentage change in total hip bone mineral density (BMD) from baseline to week 48 in t

70 an mass (ALM), quadriceps strength (QS), and bone mineral density (BMD) in 2986 men and women, aged 1

71 ed lumbar spine, total hip, and femoral neck bone mineral density (BMD) in 581 HIV-positive (94.7% re

72 identified more than 60 loci associated with bone mineral density (BMD) in adults but less is known a

73 leotide polymorphisms (SNPs) associated with bone mineral density (BMD) in adults.

74 Initiation of TDF decreases bone mineral density (BMD) in HIV-infected people.

75 Weight loss (WL) negatively affects bone mineral density (BMD) in older populations and has

76 anion study to MA.27, we compared changes in bone mineral density (BMD) in the lumbar spine and total

77 in osteoprotegerin correlate with decreased bone mineral density (BMD) in untreated HIV infection.

78 monoclonal antibody, versus teriparatide on bone mineral density (BMD) in women with postmenopausal

79 Background: Bone mineral density (BMD) is a heritable phenotype that

80 Background: Whether change in bone mineral density (BMD) is an accurate indicator of a

81 High bone mineral density (BMD) is associated with an increas

82 Bone mineral density (BMD) is highly heritable, a major

83 hrolithiasis, bone densitometry scoring, and bone mineral density (BMD) loss according to bone turnov

84 (HIV) disease before treatment contribute to bone mineral density (BMD) loss after ART initiation.

85 [control (CON)].RCE significantly attenuated bone mineral density (BMD) loss at the L2-L4 lumbar spin

86 -analysis examining isoflavone therapies and bone mineral density (BMD) loss in peri- and postmenopau

87 Bone mineral density (BMD) measured by dual-energy x-ray

88 ted data on current anthropometric measures, bone mineral density (BMD) measured by dual-energy X-ray

89 Patient bone mineral density (BMD) predicts the likelihood of os

90 g-reported parental hip fracture in a unique bone mineral density (BMD) registry linked to administra

91 Manitoba, Canada at the time of their first bone mineral density (BMD) test posttransplant (mean 1.1

92 lumbar spine bone mineral content (BMC) and bone mineral density (BMD) was assessed using DXA.

93 Trabecular bone mineral density (BMD) was determined in each verteb

94 nd whole-body bone mineral content (BMC) and bone mineral density (BMD) were measured at age 20 y thr

95 Plasma bone turnover markers and bone mineral density (BMD) were performed at weeks 0, 12

96 ion between protein intake with fracture and bone mineral density (BMD) within the Women's Health Ini

97 ated deficiencies and cardiovascular health, bone mineral density (BMD), and physical fitness.

98 ally relevant to osteoporosis, assessed from bone mineral density (BMD), as a new potential target of

99 content and density, cortical and trabecular bone mineral density (BMD), BMC, and bone area at the 4%

100 stigated their prospective associations with bone mineral density (BMD), bone area, and bone mineral

101 Offspring total body bone mineral density (BMD), bone mineral content (BMC),

102 ially vegan diets, are associated with lower bone mineral density (BMD), but this does not appear to

103 o, usual care, or active control in terms of bone mineral density (BMD), fractures, and safety in pat

104 ions aimed at preventing fracture, improving bone mineral density (BMD), or preventing or delaying os

105 tion between B-vitamin status biomarkers and bone mineral density (BMD), risk of osteoporosis, and bi

106 bl-Wnt16 mice displayed increased total body bone mineral density (BMD), surprisingly caused mainly b

107 were accompanied by diminishing weight loss, bone mineral density (BMD), trabecular thickness, trabec

108 However, obese people have a higher bone mineral density (BMD), which suggests that low 25(O

109 ide association studies are also involved in bone mineral density (BMD).

110 isease diagnosed primarily by measurement of bone mineral density (BMD).

111 nfection is associated with 2% to 6% loss of bone mineral density (BMD).

112 useful tools to screen for reduced skeletal bone mineral density (BMD).

113 LS)-, total hip (HIP)- and femoral neck (FN)-bone mineral density (BMD).

114 in low estrogen levels, which in turn affect bone mineral density (BMD).

115 actor for osteoporotic fractures and altered bone mineral density (BMD).

116 volume (BV), bone mineral content (BMC), and bone mineral density (BMD).

117 asing in children and is associated with low bone mineral density (BMD).

118 linically relevant, significant decreases in bone mineral density (BMD).

119 aviour and activity, response to therapy and bone mineral density (BMD).

120 e-wide association study summary datasets of bone mineral density (BMD).

121 elationship of those variables to changes in bone mineral density (BMD).

122 rong patient-level risk factors included low bone mineral density (hazard ratio [HR], 0.53 per unit i

123 y lean mass (TB-LM) and total-body less head bone mineral density (TBLH-BMD) regions in 10,414 childr

124 Of six adults that were subjected to bone mineral density analysis, three presented with oste

125 eal (P=0.001) and volumetric (P<0.001-0.006) bone mineral density and 1.5- to 1.8-fold increases in r

126 Bone mineral density and abdominal fat and paraspinal mu

127 Alveolar bone mineral density and alveolar bone volume were quant

128 s, romosozumab was associated with increased bone mineral density and bone formation and with decreas

129 not dwarfed and had significantly increased bone mineral density and bone mineral content in femurs

130 ation and finite element analysis to measure bone mineral density and bone strength at the hip and sp

131 I) is a genetic disorder that results in low bone mineral density and brittle bones.

132 ning markers of bone turnover and whole-body bone mineral density and content were not affected by ei

133 f calcium supplements to prevent declines in bone mineral density and fractures is widespread in the

134 Hip and spine bone mineral density and glomerular filtration were each

135 Patients with type 1 diabetes have lower bone mineral density and higher risk of fractures.

136 g from autism have been reported to have low bone mineral density and increased risk for fracture, ye

137 genetic factors with pleiotropic effects on bone mineral density and lean mass.Bone mineral density

138 ffects on bone mineral density and lean mass.Bone mineral density and lean skeletal mass are heritabl

139 mine if computed tomographic (CT) metrics of bone mineral density and muscle mass can improve the pre

140 L5HU and PsoasL4-5, which are surrogates for bone mineral density and muscle mass, respectively, were

141 ignificantly higher bone volume/total volume bone mineral density and number of osteoblasts in the ra

142 nce of viral suppression and led to improved bone mineral density and renal function.

143 In this population-based cohort study, bone mineral density and risk factors were used to calcu

144 istal radius was performed and evaluated for bone mineral density and trabecular and cortical bone mi

145 Osteopenia, osteoporosis, and low bone mineral density are frequent in patients with HIV.

146 Most interventions used bone mineral density as a surrogate outcome, despite com

147 We assessed the 96 week loss of bone mineral density associated with a nucleoside or nuc

148 ores of less than -2.0, mean change of spine bone mineral density at 2 years did not differ significa

149 of a CpG site proximal to the NFIX locus and bone mineral density at age 17.

150 mide had a significantly smaller decrease in bone mineral density at hip (mean change -0.10% [95% CI

151 ry end points included percentage changes in bone mineral density at other sites and in markers of bo

152 01), and a significantly smaller decrease in bone mineral density at spine (mean % change -1.30 vs -2

153 ry, ECSW was associated with preservation of bone mineral density at the central skeleton; however, i

154 t was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months.

155 ere associated with significant increases in bone mineral density at the lumbar spine, including an i

156 Bone mineral density at the spine, hip, and wrist were m

157 , vs. 55.0 to 52.3 kg [5% decrease]), as did bone mineral density at the total hip (grams per square

158 was also associated with large increases in bone mineral density at the total hip and femoral neck,

159 ciation between serum PFAS concentration and bone mineral density at total femur (TFBMD), femoral nec

160 entage changes in lumbar spine and total hip bone mineral density at week 48, assessed by dual energy

161 rnib monotherapy treatment reveal additional bone mineral density benefit but likely no added cardiov

162 d a smaller decrease in lumbar spine and hip bone mineral density but greater accumulation of limb an

163 Compared with baseline, 12-month areal bone mineral density by DXA did not change significantly

164 micro-computed tomographic (CT) imaging and bone mineral density by peripheral quantitative CT scann

165 In resource-limited settings, FRAX without bone mineral density can be substituted for DXA.

166 absorptiometry (DEXA) was used to determine bone mineral density changes in TDF-exposed patients.

167 en switching from teriparatide to denosumab, bone mineral density continued to increase, whereas swit

168 nce of pathogenic variants in RECQL4 and low bone mineral density correlate with the history of incre

169 We also apply our approach to bone mineral density data, and again final models contai

170 There were no bone architectural or bone mineral density differences by microCT.

171 her fracture genetic risk score (Fx-GRS) and bone mineral density genetic risk score (BMD-GRS) modify

172 ations in Col6a5 that underlies variation in bone mineral density in both mouse and human.

173 The effects of corticosteroids on bone mineral density in children seem to be more amenabl

174 ested a trend of less vertical bone gain and bone mineral density in controls (P >0.05).

175 ion of nutritional deficiencies and study of bone mineral density in high-risk patients.

176 t testosterone replacement therapy increases bone mineral density in hypogonadal men, including men w

177 sorptive agents are clearly able to preserve bone mineral density in men on ADT, whereas other approa

178 restores reproductive capacity and increases bone mineral density in patients with hypothalamic ameno

179 tch study, we aimed to assess the changes in bone mineral density in postmenopausal osteoporotic wome

180 At week 48, the mean percentage loss in bone mineral density in the lumbar spine was greater in

181 reater than -2.0 at baseline, mean change of bone mineral density in the spine at 2 years did not dif

182 48 months, the primary outcome of mean spine bone mineral density increased by 18.3% (95% CI 14.9-21.

183 Similarly, femoral neck bone mineral density increased more in the teriparatide

184 ineral density secondary outcomes, total hip bone mineral density increased more in the teriparatide

185 ion Combined assessment of bone strength and bone mineral density is a cost-effective strategy for os

186 Systemic and persistent low bone mineral density is an independent prognostic factor

187 uce fragility fractures in patients with low bone mineral density is beyond the scope of the guidelin

188 ar growth attenuation and adverse effects on bone mineral density is generally low but should be cons

189 Bone mineral density is known to be a heritable, polygen

190 The pathogenesis of declining bone mineral density is poorly understood but it is inhe

191 s in eight loci, including seven established bone mineral density loci: WNT4, GALNT3, MEPE, CPED1/WNT

192 y, whereas ST-SPI diet only reduced cortical bone mineral density loss 3 wk post-OVX.

193 cant component of the pathophysiology of the bone mineral density loss associated with Inflammatory B

194 efficacy but with decreased renal injury and bone mineral density loss compared with TDF.

195 Bone mineral density loss has been described in TDF-trea

196 Total hip bone mineral density loss was similarly greater at week

197 ombined teriparatide and denosumab increased bone mineral density more than either drug alone.

198 f fluoride's effects showed some increase in bone mineral density of adolescents and young adults in

199 Small reductions (<2%) in mean bone mineral density of hip and spine were detected by d

200 D status were demonstrated to reduce loss of bone mineral density on long-duration International Spac

201 e percent change in posterior-anterior spine bone mineral density over 4 years.

202 e revealed increased remodelling and reduced bone mineral density portrayed by increased carbonate to

203 , and suppression of ectopic calcifications, bone mineral density reduction, pulmonary emphysema and

204 For the bone mineral density secondary outcomes, total hip bone

205 Lumbar spine bone mineral density showed a mean increase by day 85 an

206 risk factors for osteoporotic fractures, and bone mineral density surveillance) originated from the q

207 commended in postmenopausal women who have a bone mineral density T score of -2.5 or less, a history

208 erate or one severe vertebral fracture and a bone mineral density T score of less than or equal to -1

209 The Mann-Whitney test was used to compare bone mineral density T scores and elastic moduli between

210 Her bone mineral density T scores are -2.6 at the lumbar spi

211 For bone mineral density T scores at the femoral neck, biome

212 eak relationships between elastic moduli and bone mineral density T scores in patients with fractures

213 lationship (R(2)) between elastic moduli and bone mineral density T scores was assessed.

214 .62 GPa; P = .01-.02), but no differences in bone mineral density T scores.

215 ient subgroups, including in patients with a bone mineral density T-score of -1 or higher at baseline

216 CI 0.31-0.64], p<0.0001) and in those with a bone mineral density T-score of less than -1 already at

217 s associated with significantly less loss of bone mineral density than a standard regimen containing

218 urgery, the hind limb had significantly less bone mineral density than contralateral controls, confir

219 pids, and greater decreases from baseline in bone mineral density than did those who received placebo

220 ficantly smaller mean percentage declines in bone mineral density than those receiving tenofovir diso

221 Bone mineral density was assessed in those patients with

222 Normal bone mineral density was detected in 2/8 case, osteopeni

223 Bone mineral density was expressed as Z scores (standard

224 Bone mineral density was measured at lumbar spine and th

225 Bone mineral density was measured at the lumbar spine an

226 DEXA for measuring bone mineral density was performed on every patient.

227 Concomitantly, alveolar bone mineral density was significantly lower in all thre

228 After 48 months, radius bone mineral density was unchanged in the teriparatide t

229 Total and trabecular bone mineral density were significantly lower (-13.4% an

230 t model, there is a large loss of trabecular bone mineral density without apparent proportional chang

231 Mean bone mineral density z scores (lumbar spine and femur) r

232 after treatment started (including data for bone mineral density).

233 Bone mineral density, abdominal fat area, and paraspinal

234 erum type I collagen C-telopeptide), low hip bone mineral density, absence of urticaria pigmentosa, a

235 rception of health by a visual analog scale, bone mineral density, and body composition at baseline a

236 ice by adoptive transfer, and bone turnover, bone mineral density, and indices of bone structure and

237 Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the U.S. popul

238 in other frailty measures, body composition, bone mineral density, and physical functions.

239 1 y of age and in a subgroup at 2 y of age : Bone mineral density, bone mineral content (BMC), area-a

240 p-null (Bsp(-/-)) mice exhibit reductions in bone mineral density, bone turnover, osteoclast activati

241 tients with chronic hepatitis B have reduced bone mineral density, but the reduction is limited to 1

242 ect to their metabolic bone status including bone mineral density, calcium kinetics studies, and mark

243 deletion of Cx37 (Cx37(-/-)) exhibit higher bone mineral density, cancellous bone volume, and mechan

244 these antibodies led to a marked increase in bone mineral density, consistent with inhibition of oste

245 nes were significantly associated with spine bone mineral density, including BDNF, PDE4D, and SATB2,

246 ovements in blood pressure, body mass index, bone mineral density, lipid levels, or quality-of-life m

247 splay skeletal alterations including reduced bone mineral density, modified bone structure and distin

248 Other than increased bone mineral density, no improvement rates exceeded thos

249 s between groups in laboratory test results, bone mineral density, or body composition.

250 Despite normal to high bone mineral density, patients with type 2 diabetes (T2D

251 we show that Ppia(-/-) mice demonstrate low bone mineral density, reduced osteoblast numbers, and in

252 users should not routinely screen or monitor bone mineral density, serum creatinine, magnesium, or vi

253 revented the reduction in spinal and femoral bone mineral density, spinal bone volume/tissue volume,

254 ostin inhibition could be applied to enhance bone mineral density, stability, and regeneration in non

255 eplacement therapy has been shown to improve bone mineral density, studies have also linked bone loss

256 n increases in bone formation biomarkers and bone mineral density, suggesting that sclerostin inhibit

257 hese mice displayed significant reduction in bone mineral density, trabecular bone volume, and cortic

258 ng bone disease that is characterised by low bone mineral density, typically assessed using dual-ener

259 ex, serum type I collagen C-telopeptide, hip bone mineral density, urticaria pigmentosa, and alcohol

260 oncentration, serum phosphate concentration, bone mineral density, vascular calcification, renal func

261 These groups exhibited decreased bone mineral density, volume fraction, and bone formatio

262 t mass, lean mass, bone mineral content, and bone mineral density, was determined by dual-energy X-ra

263 rial which tested the effect of denosumab on bone mineral density, we assessed the impact of this dru

264 Texture parameters, but not bone mineral density, were associated with lowest lifeti

265 the loss of total, trabecular, and cortical bone mineral density, whereas ST-SPI diet only reduced c

266 AS concentrations were associated with lower bone mineral density, which varied according to the spec

267 n associated with renal toxicity and reduced bone mineral density.

268 libido, vasomotor instability, and decreased bone mineral density.

269 ion, and then develop anemia and a decreased bone mineral density.

270 omy-induced osteoporosis results in improved bone mineral density.

271 exposure were independent predictors of low bone mineral density.

272 evious aromatase inhibitor use, and baseline bone mineral density.

273 n IBD patients and to IBD-associated loss of bone mineral density.

274 sumab, however, results in rapidly declining bone mineral density.

275 t or blunt the effects of corticosteroids on bone mineral density.

276 at individuals with RTS have decreased areal bone mineral density.

277 ea, but there were no such associations with bone mineral density.

278 sa that is independent of that provided with bone mineral density.

279 e surface, accompanied by a dramatic loss of bone mineral density.

280 ut not CD8+ T cells significantly diminished bone mineral density.

281 ears in a Women's Health Initiative study of bone mineral density.

282 nd was associated with a smaller decrease in bone mineral density; however, greater resistance and ga

283 with a significant increase in femoral neck bone mineral density; vascular calcification remained un

284 Low bone-mineral density (BMD) is particularly concerning, b

285 usal associations between blood pressure and bone-mineral density with type 2 diabetes.

286 formation result in the loss of calcium and bone mineral during space flight, which alters the endoc

287 Bone mineral elastic modulus was similar at 24 hours but

288 ivo observations support the hypothesis that bone mineral formation proceeds via disordered precursor

289 Using the known affinity of phosphonates for bone minerals in a model system, two families of bifunct

290 Here, a bone mineral inspired protein stabilization strategy is

291 ural model that we deduce from this work for bone mineral is a layered structure with thin apatitic p

292 Bone mineral is largely composed of hydroxyapatite (HA)

293 ted areas do not have significant effects on bone mineral measures.

294 Alterations in bone mineral metabolism occur when kidney function decli

295 ivative (EMD) combined with either a natural bone mineral (NBM) or beta-tricalcium phosphate (beta-TC

296 s of grafting materials, including a natural bone mineral (NBM), demineralized freeze-dried bone allo

297 whereas the latter conferred a quasi-normal bone mineral phenotype through compensatory homeostatic

298 ain a number of known structural features of bone mineral: the thin, plate-like morphology of mature

299 mechanical properties, rather than increased bone mineral turnover.

300 the relevance of such a structure in native bone mineral, we present for the first time, to our know